Cargando…
P10 Ceftazidime/avibactam for OXA-48 urinary tract infections—a 12 month remissive study
BACKGROUND: Ceftazidime/avibactam is a novel antibiotic for MDR bacterial infections. Despite its high cost, from 1 January 2022 to 31 December 2022, 23 patients out of 230 hospital beds at the Hospital of Cascais received it. Seven of these patients had OXA-48-producing urinary tract infections (UT...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395424/ http://dx.doi.org/10.1093/jacamr/dlad077.014 |